Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-center Investigational Study of IMMray™ PanCan-d Diagnostic Assay for Early Detection of Pancreatic Ductal Adenocarcinoma in High-risk Populations

NCT03693378 is registered in ClinicalTrials.gov with Immunovia, Inc. as lead sponsor.

NCT NCT03693378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03693378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-center Investigational Study of IMMray™ PanCan-d Diagnostic Assay for Early Detection of Pancreatic Ductal Adenocarcinoma in High-risk Populations
Lead sponsor
Immunovia, Inc.
Phase
Observational
Overall status
Completed
Start date
January 19, 2016
Completion date
November 12, 2021
Enrollment
1,349 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

familial pancreatic cancer, fammm - familial atypical mole malignant melanoma syndrome, pancreatic ductal adenocarcinoma